NAUT Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. operates as biotech company that develops a platform using computational techniques, cloud computing, AI technologies, and blood tests to detect cancer and potentially other health issues at an early stage. Nautilus Biotechnology, Inc. was formerly known as Ignite Biosciences, Inc. The company was incorporated in 2016 and is based in San Carlos, California.  This company has other shares of common stock that are publicly traded. See the "related symbols" tab.

$10.19  -0.26 (-2.49%)
As of 06/14/2021 13:28:19 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Unknown
Index country:  USA
Country of incorporation:  
IPO date:  06/10/2021
Outstanding shares:  0
Average volume:  274,419
Market cap:   $0
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy